Needham & Company reiterates a 'Buy' on Cubist Pharmaceuticals (NASDAQ: CBST), PT increased from $27 to $33.

Needham analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE